Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin.
Dejan MilentijevicJennifer H LinYen-Wen ChenEmily KoganShubham ShrivastavaErik SjoelandMark J AlbertsPublished in: Journal of medical economics (2021)
Total all-cause costs of care increased in the post-stroke period, and particularly in the patients treated with warfarin relative to those treated with rivaroxaban. The lower rate of stroke in the rivaroxaban cohort suggests that greater pre- to post-stroke cost increases result from more strokes occurring in the warfarin cohort.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- healthcare
- direct oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- heart failure
- percutaneous coronary intervention
- palliative care
- venous thromboembolism
- quality improvement
- pain management
- combination therapy
- pulmonary embolism
- newly diagnosed
- acute coronary syndrome
- blood brain barrier
- social media